title: Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".
authors.affiliation: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Offer
authors.affiliation: 1] Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA [2] Mayo Clinic Cancer Center, Rochester, Minnesota, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Diasio
mesh_terms: D001741:Black or African American / Q000235:genetics*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil